Founded December 2016 (incubated)
Stage Business development
Investors The Trendlines Group; Technion-Israel Institute of Technology
CEO Hezkiah Tsoory
liberDi’s multidisciplinary team of experts developed a life-changing solution for patients requiring dialysis. The Company’s portable, automatic dialysis system significantly reduces the burden of performing dialysis, improves treatment benefits, and and increases health care efficiency.
The system is engineered with unique, innovative properties to give increased freedom and greatly improved quality of life:
The Company’s healthcare IT solution reduces human errors and is expected to reduce treatment time and infection rates.
The liberDi system presents the paradigm-changing technological system to give greater numbers of patients with end-stage renal disease (ESRD) the opportunity to choose portable peritoneal dialysis as their treatment modality, which will by give them greater control over their daily treatment regimen and significantly improve their quality of life.
liberDi’s results: Improved patient satisfaction, improved treatment outcomes, and reduced health care costs that allow a new, disruptive business model in the dialysis market.
See liberDi in BioTuesdays.
The market seeks an effective, easy-to-use dialysis solution for improved treatment benefits and reduced health care costs.
Portable, smart dialysis system • Reduced risk of infection • Easy operation • U.S.: 3.2 million people with ESRD • U.S.: $30.9 billion Medicare spending on ESRD
See the liberDi animation.
Hezkiah Tsoory, Founder & CEO: Extensive experience in international business, operations, R&D; former VP Business Development, Nanocell; COO, D Medical Industries (TASE, Nasdaq: DMED), COO, MCS (TASE: MDCL); VP Operations, Mentorwave; VP Manufacturing, Power Paper
Over 20 years’ experience as a specialist in nephrology and hypertension; Head, Department of Nephrology and Hypertension, Carmel Medical Center, Haifa, Israel; VP, Israeli Society of Nephrology and Hypertension
Head of Dialysis Unit, Carmel Medical Center, Haifa, Israel; specialist in nephrology and internal medicine; 20 years’ experience in nephrology; organizer, Israel PD Academy
Previously, Head of the Institute of Nephrology, Rabin Medical Center (Beilinson & Hasharon hospitals), Petah Tikva, Israel. Extensive clinical and research experience in the field of nephrology in general and peritoneal dialysis in particular
Head, Peritoneal Dialysis Unit, Imperial College Kidney and Transplant Centre, Hammersmith Hospital, London, UK; co-organizer, UK PD Academy; extensive research and education related to outcomes of older patients on dialysis; Chair, Guidelines Committee, International Society of Peritoneal Dialysis
Dialysis presents a life-sustaining treatment for patients with end-stage renal disease (ESRD). For many patients, dialysis often becomes the focal point of their life due to the time they spend traveling to and from treatment sessions and the time dedicated to the treatment itself. Moreover, ESRD is tremendously expensive: Medicare costs in the United States alone reach $31 billion annually.
Portable dialysis devices have the potential to improve quality of life by allowing patients to continue with their daily activities while undergoing dialysis.
Unfortunately, however, existing home dialysis systems are bulky, expensive and “suffer” from a particularly cumbersome setup and complicated treatment regimen. They may also increase the risk of infection. For these reasons, and more, only 11% of dialysis patients choose to receive peritoneal dialysis (PD) treatment at home.
With 2.5 million people undergoing dialysis worldwide, and increasing >5% yearly (due to aging population and the rise of diabetes, hypertension, and obesity), the dialysis market is in need of an effective, easy-to-use solution for improved treatment benefits and reduced health care efficiency. According to a new report from KBV Research, Global Dialysis Market (2017-2023), the global dialysis market is expected to attain a market size of $124 billion by 2023, with a CAGR of 5.3% during the forecast period.